537 related articles for article (PubMed ID: 8519652)
41. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
42. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
43. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay.
Hida T; Ueda R; Takahashi T; Watanabe H; Kato T; Suyama M; Sugiura T; Ariyoshi Y; Takahashi T
Cancer Res; 1989 Sep; 49(17):4785-90. PubMed ID: 2547517
[TBL] [Abstract][Full Text] [Related]
44. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer.
Oguri T; Isobe T; Suzuki T; Nishio K; Fujiwara Y; Katoh O; Yamakido M
Int J Cancer; 2000 Apr; 86(1):95-100. PubMed ID: 10728601
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
46. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.
Sears CR; Cooney SA; Chin-Sinex H; Mendonca MS; Turchi JJ
DNA Repair (Amst); 2016 Apr; 40():35-46. PubMed ID: 26991853
[TBL] [Abstract][Full Text] [Related]
47. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line.
Meijer C; Mulder NH; Timmer-Bosscha H; Zijlstra JG; de Vries EG
Cancer Res; 1987 Sep; 47(17):4613-7. PubMed ID: 3040227
[TBL] [Abstract][Full Text] [Related]
48. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
49. [Trial of radiation and cisplatin, carboplatin combination chemotherapy for advanced cancer (W-platinum chemoradiotherapy].
Kato M; Akimoto S; Akimoto K; Matsui H; Itokawa Y; Tatsuta K; Tanaka T; Komatsu T; Nakaoka Y; Miyata K; Okada H; Genno M; Sekikawa S; Takada A; Kizu O; Okuyama C; Maeda T
Gan To Kagaku Ryoho; 1997 Apr; 24(6):723-7. PubMed ID: 9126311
[TBL] [Abstract][Full Text] [Related]
50. In vitro toxicity of (191)Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180).
Areberg J; Johnsson A; Wennerberg J
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1275-80. PubMed ID: 10725641
[TBL] [Abstract][Full Text] [Related]
51. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Fishel ML; Delaney SM; Friesen LD; Hansen RJ; Zuhowski EG; Moschel RC; Egorin MJ; Dolan ME
Mol Cancer Ther; 2003 Jul; 2(7):633-40. PubMed ID: 12883036
[TBL] [Abstract][Full Text] [Related]
53. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
54. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
56. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells.
Di Felice V; Lauricella M; Giuliano M; Emanuele S; Vento R; Tesoriere G
Int J Oncol; 1998 Aug; 13(2):225-32. PubMed ID: 9664115
[TBL] [Abstract][Full Text] [Related]
57. Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.
Nakamura T; Koizumi F; Kaneko N; Tamura T; Chiwaki F; Koh Y; Akutagawa S; Saijo N; Nishio K
Jpn J Cancer Res; 2001 Jun; 92(6):597-602. PubMed ID: 11429046
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
59. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
60. The influence of platinum drugs on the radiation response of rat kidneys.
van Rongen E; Kuijpers WC; Baten-Wittwer A
Radiother Oncol; 1994 May; 31(2):138-50. PubMed ID: 8066193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
